How many drugs treat Pulmonary thromboembolism?

Drug Landscape tracks 5 marketed treatments for Pulmonary thromboembolism (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pulmonary-thromboembolism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pulmonary thromboembolism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary thromboembolism (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary thromboembolism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Arixtra	FONDAPARINUX	Mylan Ireland Ltd	Factor Xa Inhibitor	Coagulation factor X	2001-01-01
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Heparin Sodium In Plastic Container	HEPARIN	Merck & Co.	Anti-coagulant	Antithrombin-III	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Arixtra	Arixtra	LifeBridge Health		Antithrombin-III, Coagulation factor X

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Fresenius Kabi · 1 drug in Pulmonary thromboembolism
Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in Pulmonary thromboembolism
LifeBridge Health · 1 drug in Pulmonary thromboembolism
Merck & Co. · 1 drug in Pulmonary thromboembolism
Mylan Ireland Ltd · 1 drug in Pulmonary thromboembolism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary thromboembolism:

Cite this brief

Drug Landscape (2026). Pulmonary thromboembolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-thromboembolism. Accessed 2026-06-10.

Pulmonary thromboembolism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing